Compare BFS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | ESPR |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 731.9M |
| IPO Year | N/A | 2013 |
| Metric | BFS | ESPR |
|---|---|---|
| Price | $34.28 | $3.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $44.00 | $8.75 |
| AVG Volume (30 Days) | 41.2K | ★ 16.9M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $5.67 | $12.81 |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $29.16 | $0.79 |
| 52 Week High | $35.45 | $4.18 |
| Indicator | BFS | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 70.22 |
| Support Level | $32.56 | $3.11 |
| Resistance Level | $34.99 | $3.18 |
| Average True Range (ATR) | 0.77 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 67.74 | 21.43 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.